Christopher Yasenchak, MD
Basic profileChristopher Yasenchak is an Oncology physician affiliated with Willamette Valley Cancer Institute and Research Center. OpenAlex indexes 103 publications with 1,306 citations (h-index 16).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingIndustry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Bristol Myers SquibbProgram year20255 paymentsResearch$64,443
- TakedaProgram year20257 paymentsResearch$33,277
- SanofiProgram year20253 paymentsResearch$28,500
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
46.3%Iron, parenteral preparations24%Ferric carboxymaltose100%Part B, office-administered≥12 patientsErythropoiesis-stimulating Agent22.2%Darbepoetin alfa100%Part B, office-administered≥11 patients+ 1 more class in this area
Cancer & immunology
36.2%PD-1 inhibitor28.1%Pembrolizumab53%Nivolumab47%Part B, office-administered≥14 patientsMicrotubule Inhibitor6.7%Paclitaxel100%Part B, office-administered≥11 patients+ 9 more classes in this area
Metabolism & gastrointestinal
14.3%Substance P/Neurokinin-1 Receptor Antagonist11.6%Aprepitant100%Part B, office-administered≥21 patientsSerotonin-3 Receptor Antagonist2.5%Palonosetron hcl55%Granisetron hydrochloride40%Ondansetron Hcl5%Part D + Part B≥34 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
Journal of Clinical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Jeff Sharman, MD
Willamette Valley Cancer Institute and Research Center
James Butrynski, MD
Willamette Valley Cancer Institute and Research Center
Merideth Wendland, MD
Willamette Valley Cancer Institute and Research Center
Carl June, MD
University of Pennsylvania
Stuart Orkin, MD
Harvard Medical School
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”